Health
Johnson & Johnson’s Coronavirus Vaccine Candidate Efficacious in Pre-Clinical Studies; Human Testing Has Begun – The Motley Fool
The company aims to start a phase 3 clinical trial for Ad26.COV2-S in September.
Johnson & Johnson(NYSE:JNJ) has gained some ground in the coronavirus vaccine race. On Thursday, the pharmaceutical and consumer goods company announced that in pre-clinical studies, its Ad26.COV2-S vaccine candidate had demonstrated effectiveness in protecting on non-human primates from infection with SARS-CoV-2.
In contrast to other coronavirus vaccine candidates — such as the one many observers view as the most promising, Moderna’s mRNA-1273 — Johnson & Johnson’s produced its respo…
-
Noosa News15 hours agoHockey coach in Arana Hills charged with grooming and sexual offences against teenage girls
-
General15 hours agoWoman killed and man injured in shark attack on NSW Mid North Coast
-
General24 hours agoFormer Marine Paul Doyle pleads guilty to Liverpool FC parade car ramming charges
-
Noosa News16 hours agoDepartment of Transport and Main Roads orders shutdown of North Ipswich Free Shop